Abstract. Amyloid-β (Aβ) peptide, a cleavage product of the amyloid-β protein precursor (AβPP), has been reported to be detected in the intracellular compartment. Most studies reporting the presence of intracellular Aβ are based on the use of immunohistochemistry. In this study, the presence of AβPP and Aβ was assessed by applying immunohistochemistry in postmortem human brain tissue samples obtained from 10 neurologically intact subjects, the youngest being 2 years of age, one aged with mild cognitive impairment, 14 neurologically diseased, and in one brain biopsy sample obtained from a subject with normal pressure hydrocephalus. Intracellular immunoreactivity was detected in all ages independent of the disease state or existence of extracellular Aβ aggregates with all antibodies directed to AβPP, with three Aβ antibodies (4G8, 6E10, and 82E1), clones that are unable to distinguish Aβ from AβPP. These results suggest that it is AβPP rather than Aβ that is detected intracellularly when using the antibodies listed above. Furthermore, the staining results varied when different pretreatment strategies were applied. Interestingly intracellular Aβ was detected with antibodies directed to the C-terminus of Aβ (neoepitope) in subjects with Alzheimer's disease. The lack of intracellular immunoreactivity in unimpaired subjects, when using antibodies against neoepitopes, may be due to a lack or a low level of the protein that is thus undetectable at light microscopic level by immunohistochemistry method. The staining results and conclusions depended strongly on the chosen antibody and the pretreatment strategy and thus multiple antibodies must be used when assessing the intracellular accumulation of Aβ.
INTRODUCTION
Already by the late 1980s, intracellular amyloid-β peptide (iAβ) [1] was reported to be seen in the brains of both subjects with Alzheimer's disease (AD) and controls applying an antibody that is commonly used in neuropathological diagnostics (clone 4G8). A review of the literature reveals that while applying various commercial antibodies (Table 1) , iAβ has been reported to be detected in cell culture, in the brains of wild and transgenic animals, in brains obtained from subjects with Down's syndrome, AD, and HIV, and in young drug abusers as well as in brains obtained from children and aged without any known neurological disorders . It is noteworthy and disturbing that there is considerable variation in results not only while applying a different antibody but even with the Fig. 1 . A schematic presentation of the amyloid-β protein precursor (AβPP) where the epitope regions recognized by the antibodies used in this study are marked with black (AβPP/Aβ) and gray bars (Aβ neoepitopes). Clone 82E1 is raised against Aβ 1−16 (Immuno-Biological Laboratories). Clone 6E10 is raised against Aβ 1−17 (Signet) [3, 56, 57] . Clone 6F3D is raised against Aβ 8−17 (DakoCytomation) [3, 58] . Clone 4G8 (Signet) is raised against Aβ17-24 (Signet) [3, 58] . Clone 12F4 is raised against Aβ 1−42 (Covance) and is reactive to C-terminus of Aβ and is specific for the isoform ending at the 42nd amino acid. Clone 22C11, is raised against recombinant Alzheimer precursor A4 fusion protein; clone 40.10, is raised against the sequence between Kunitz protease inhibitor domain and the beta-amyloid region (Novocastra). The specificity of polyclonal antibodies as provided by the manufacturer: poly 44-348 (Biosource/Invitrogen), poly 44-344 (Biosource/Invitrogen), and poly A 8717 (Sigma). Aβ, amyloid-β. same antibody (see Table 1 ).
Aβ consists of 40-43 amino acids and is a cleavage product of the transmembrane amyloid-β protein precursor (AβPP), encoded as a single-copy gene on chromosome 21 [24] [25] [26] [27] [28] . AβPP is widely expressed in the brain. The cleavage of AβPP has been reported to occur when AβPP is located at the plasma membrane, endoplasmic reticulum, endosomal and lysosomal membranes [29] , trans-Golgi network [30] , and mitochondrial membrane [31] . Thus, the cleavage product, Aβ, could be expected to be found in the intracellular compartment.
Most studies reporting the presence of iAβ (Table 1 ) are based on the use of immunohistochemistry (IHC). In IHC, antibodies, which recognize a specific sequence of amino acids, are used, i.e., an antibody recognizes usually only small part of a longer peptide (Fig. 1 ).
With respect to both AβPP and Aβ, numerous commercial and in house monoclonal and polyclonal antibodies are available. As is seen in Fig. 1 , some of the amino acid sequences, i.e., epitopes, are shared by Aβ and AβPP. It has been demonstrated that clone 6E10, which is specific for the sequence 4-13 of human Aβ, detects not only Aβ but also AβPP [32, 33] , and clone 4G8, which is directed to the mid-portion of Aβ, reacts to Aβ and AβPP derivatives in Western blots [34] . Thus, intracellular staining with monoclonal antibodies such as 6E10 or 4G8 may be detecting AβPP, various AβPP derivatives, or Aβ. Only in the 1990s did antibodies against the C-terminus (neopitopes) of Aβ (Aβ 40 and Aβ 42 ), i.e., antibodies that are able to differentiate Aβ from AβPP, become available. It is noteworthy that despite the reports indicating that many of the commonly used antibodies are unable to distinguish Aβ from AβPP, clone 4G8 was still being used as late as 2009 to detect iAβ in subjects with HIV [2, 12] . In addition to the use of antibodies with variable specificities, the reports listed in Table 1 are carried out on the tissue obtained from either humans or animals. It has earlier been shown that species differences may to some extent influence the findings and thus the results obtained from animal studies are not as such directly comparable with those seen in humans [35, 36] . Therefore, some of the variability listed in Table 1 might be related to species differences. However, even when applying the same antibody or investigating the same species, the results have varied as is seen from Table 1. Another possible explanation for the discrepant results is varying antigen retrieval methods [19, [37] [38] [39] [40] . It has been demonstrated that a heating protocol can often enhance the staining whereas formic acid pretreatment alone is not sufficient to visualize intracellular immunoreactivity (IR) [19, 39] . These reports have concluded that the existence of intracellular labeling may be underestimated, since many previous investigations employed only formic acid pretreatment. In summary, the tissue characteristics, choice of antibody, and modifications of pre-treatments strategy can significantly affect the outcome of an IHC labeling experiment.
The principal objective of this study was to test the reliability of the IHC technique while assessing iAβ in the routine diagnostic human postmortem material. The presence of AβPP and Aβ in the extra-and intracellular compartments was analyzed while applying the tissue microarray technique (TMA), several commercial antibodies, and several antigen retrieval methods.
MATERIAL AND METHODS

Case selection
This study was performed on surgical biopsy material and postmortem human brain tissue. The surgical sample was obtained from a patient who underwent intracranial pressure monitoring with frontal cortical biopsy for suspected normal pressure hydrocephalus. The postmortem brain tissues were sampled from the cases that had undergone an autopsy including a neuropathological examination. A total of 26 cases were included in this study; 1 surgical patient and 25 postmortem cases.
Surgical biopsy
A 75-year old female subject was operated due to normal pressure hydrocephalus. A right frontal 12 mm burr hole was made under local anesthesia and then cylindrical brain biopsies of 2 mm in diameter and 3 mm in length were taken through the burr hole. Half of the sample was fixed in 10% buffered formalin overnight and then embedded in paraffin. Seven-µm-thick serial sections were cut and placed on the SuperFrost Plusslides. The remaining half of the sample was placed in an Eppendorf tube and frozen at −70
• C.
Postmortem material
The demographics of investigated subjects are summarized in Table 2 . There were 10 unimpaired subjects (age at death 2-92 years), a 100 year old female with mild cognitive impairment, 7 subjects with AD (age at death 57-87 years), and 7 subjects with frontotemporal lobar degeneration with TAR DNA binding protein 43 positive inclusions (FTLD-TDP-43) (age at death 50-93 years). The rapidity of death was classified as proposed by Hynd and colleagues in 2003 [41] . At autopsy, the brain was placed in 10% buffered formaldehyde for at least 1 week, and then cut into 1-cm-thick coronal slices. The brain specimens were taken from 16 standard regions and embedded in paraffin. For each case, the AD related Braak stage was assessed as described earlier [42] . Accumulation of eAβ was assessed in three neocortical sections in all cases while applying clone 4G8 and the results are given as Aβ aggregates seen or not seen. The selected neuroanatomical region in the aged was the hippocampal region, in AD the temporal cortex, and in FTLD-TDP-43 the frontal cortex. The HE stained slides of 7-µm thick sections were used to select regions for the core samples to be embedded into the TMA blocks. One of the TMA blocks contained samples from subjects who had been between the ages of 2 to 100 years at death, referred to as the TMA-aging (TMAa) the other TMA block contained samples from demented subjects, i.e., TMA disease (TMAd). From each case in the TMAa, four core samples were taken to ensure the sampling of possible eAβ. For the TMAd from each AD case, a sample from temporal cortex and from each FTLD-TDP-43 case, a sample from frontal cortex was taken. Each core in TMAa and TMAd block measured 2.0 mm in diameter as recommended by Kauppinen and colleagues. The tissue microarray (TMA) block was constructed as described earlier [43, 44] . The core tissue sample from the donor blocks was taken using Beecher Instrument's Manual Tissue Arrayer 1 instrument and each core sample was inserted into previously made holes of the recipient block. The maximum Table 2 Demographics, cases included in the tissue microarray blocks (TMA) of aging (TMAa) and disease (TMAd)
Case Gender Age at Pre-mortem Primary cause of death / Postmortem Fixation AD-related pathology depth of the used punch was 8 mm, and the thickness of the recipient block was 10 mm. The resulting TMA blocks were warmed in an oven for 10 min at 57
• C to promote the adherence of the core sample to the paraffin of the recipient block. Finally, the TMA blocks were placed upside-down in stainless steel molds for cooling. Seven-µm-thick serial sections were cut using a rotating microtome from the TMA blocks and placed on SuperFrost Plus-slides.
Immunohistochemistry
Seven-µm-thick sections were deparaffinized and rehydrated according to the standard procedure. The TMA sections with the postmortem core samples and the surgical biopsy were stained employing antibodies as described in Table 3 and the following antigen retrieval methods were applied: 80% formic acid for 2, 10, 60 min and for 6 h or microwave in citrate buffer pH 6.0 3 × 5 min or a combination of microwave in citrate buffer pH 6.0 3 × 5 min and 80% formic acid for 10 min. Following the pretreatment, the sections were incubated with normal goat serum for 30 min at room temperature to block non-specific reactions. After the epitope unmasking, antibodies were applied in the dilution described in Table 3 . Then the sections were incubated overnight at 4
• C. On the following day, the sections were incubated with the biotinylated second antibody for 30 min followed by streptavidin enzyme conjugate (LABSA Zymed laboratories, South San Francisco, CA) for 30 min at room temperature. The reaction product was visualized using romulin 3-amino-9-ethyl carbazole (AEC). All immunostained sections were counterstained with Harris' haematoxylin, dehydrated, and mounted in DePex. To confirm the colocalization of positive labeling, serial sections were stained by applying the most optimal staining protocol (Table 3).
The staining results were evaluated under light microscopy. Extracellular and intracellular IR was assessed in each core and the extracellular IR was designated as being present or not. The intracellular IR, which was seen as grainy labeling in the cytoplasm, was noted as seen or not seen. In the serial sections, the colocalization was assessed under light microscopy at low and high magnifications.
RESULTS
Extracellular labeling
All commercial antibodies directed to the amino acid residues present in Aβ (82E1, 6E10, 6F3D, 4G8, Aβ 40 , Aβ 42 , 12F4) stained extracellular amyloid deposits irrespective of the antigen retrieval method. Extracellular aggregates were seen in the TMAa in cases #6, 8, 10, and 11, and as expected, in the TMAd in all cases of AD. The fleecy/diffuse aggregates were seen to the same extent independent of which commercial Aβ antibody was used. Contrary to the above, antibodies against AβPP or its derivatives (AβPP C-terminal, AβPP40.10) did not label the extracellular aggregates.
Formic acid treatment enhanced the intensity of extracellular IR and the contrast increased with up to 60 min of formic acid pretreatment. The combined pretreatment, i.e., boiling in a microwave oven 3 × 5 min in citrate buffer and incubation in 80% formic acid for 10 min, intensified the extent of eAβ labeling even further, however, the concomitant increase in the background IR decreased the contrast. Intense labeling of amyloid deposits, after boiling in a microwave oven and incubation in formic acid, led to the impression that there was an increased number of compact and a decreased number of diffuse deposits. If the antigen retrieval method was restricted to only boiling in a microwave oven this led to an overall weaker IR staining of the extracellular deposits.
Intracellular labeling
Intracellular labeling was observed with antibodies against AβPP or its derivatives in all scores in the TMAa and TMAd regardless of the antigen retrieval method. With three of seven antibodies directed to the amino acid residues present in Aβ (82E1, 6E10, 4G8), an obvious granular intracellular labeling was seen in all scores in the TMAa and TMAd and the labeling was present in cells already at the age of 2 and the IR remained high in all samples over entire age range of 2 to 100 years. The labeled grains were small and coarse and located close to the nucleus. With antibodies Aβ 40 , Aβ 42 , and 12F4, intracellular labeling was only detected in the TMAd in cores taken from the temporal cortex of AD cases (n = 7). The monoclonal antibody 6F3D did not display intracellular IR in any of the cores in the TMAa or TMAd. The mode of death did not seem to alter the amount of intracellular IR.
Antibodies directed to the N-terminus or mid portion of Aβ
The monoclonal antibody against N-terminus of Aβ, 6F3D, did not display intracellular IR regardless of which antigen retrieval method was used in any of the cores in the TMAa or TMAd. Contrary to the above, with monoclonal antibody directed to the mid-portion of Aβ, clone 4G8, intracellular labeling was seen in all TMAa and TMAd cores irrespective of age, disease state, or antigen retrieval method. However, a more intense intracellular labeling was detected in sections pretreated with heating as compared to those pretreated with formic acid. The intracellular labeling with N-terminal monoclonal antibody 6E10 was detected in the cores in TMAa and TMAd only when the combined pretreatment, i.e., boiling in the microwave oven and incubation in formic acid was used. In line with the above, when the N-terminal monoclonal antibody clone 82E1 was used, then intracellular labeling was noted with the high magnification in most cores in the TMAa (Fig. 2) and in the TMAd in two AD cases (#13, 15), and in three FTLD-TDP43 cases (#21, 22, 25) but only when the combination of heat and formic acid pretreatment was used. While applying clone 82E1, a few cells with labeling were noted in TMAa in the 2-year old child at the x200 magnification, whereas in the oldest case with additional eAβ aggregates, iAβ labeling was seen in almost every cell. To summarize, the combination of heat and formic acid was essential to visualize the intracellular staining with antibodies such as 6E10 and 82E1, whereas the intracellular staining with monoclonal antibody 4G8 was seen regardless of antigen retrieval method.
When comparing the images of serial sections and assessing neurons with identifiable nuclei, intracellular labeling was noted in the same cell with antibodies 4G8 or 6E10 and AβPP 22C11 (Fig. 3) .
Antibodies directed to the C-terminus of Aβ
The intracellular staining with the polyclonal antibodies directed to the neoepitopes, Aβ 40 and Aβ 42 , and the monoclonal antibody Aβ 42 , was not detected in the cores in TMAa, even though four of the TMAa core samples displayed additional eAβ (#6, 8, 10, and 11). Interestingly in the TMAd, intracellular labeling was seen with both mono-and polyclonal Aβ antibodies in all cores taken from the temporal cortex of AD cases (n = 7) displaying eAβ aggregates, most being in Braak stages V to VI (Table 2, Fig. 4) . The labeling Fig. 1 and Table 3 . Note that with all antibodies intracytoplasmic perinuclear grainy labeling was seen. Some antibodies directed to AβPP also strongly labeled the neuropil. was seen at the high magnification and based on the cytological features; the cells were either neurons or glial cells. It is noteworthy that some labeled grains were also seen in the neuropil complicating the interpretation of the staining results. These results were obtained regardless of which of the following antigen retrieval method was used: 80% formic acid, or microwave in citrate buffer pH 6.0 3 × 5 min, or a combination of microwave in citrate buffer pH 6.0 3 × 5 min and 80% formic acid for 10 min.
Surgical sample
In the surgical biopsy, no eAβ aggregates were seen with any of the applied antibodies. Intracellular labeling was seen with antibodies 6E10, 4G8, 82E1, AβPP22C11, AβPP 40.10, and AβPP C-terminus (Fig. 5) . No IR was seen when applying mono-or polyclonal C-terminal Aβ antibodies.
DISCUSSION
In the present study, the eAβ IR was repeatedly detected with antibodies directed to the amino acid residues present in the Aβ, whereas no extracellular IR was noted with antibodies directed to the AβPP or its derivatives. This finding confirms earlier reports that extracellular aggregates consist of Aβ rather than AβPP. In contrast to the clear results with respect to the extracellular labeling, the staining results regarding the iAβ were variable and dependent on both the chosen antibody and the antigen retrieval method.
Seven different commercial antibodies (4G8, 6E10, 82E1, 6F3D, Aβ 40 , Aβ 42 , 12F4) directed to the N-or C-terminus or mid-portion of the Aβ fragment were used in the present study. All of these antibodies have been claimed to recognize Aβ in the tissue according to their specifications. With three (4G8, 6E10, 82E1) of these seven antibodies, intracellular IR was detected in all cases in the cores in TMAa and TMAd independent of disease state, and it is noteworthy that the IR was already seen at the age of two years. Contrary to the above, with the C-terminal antibodies, i.e., Aβ 40 , Aβ 42 , and 12F4, the iAβ IR was only detected in the AD cases. Interestingly, monoclonal antibody 6F3D did not label the intracellular compartment with any of the used techniques in any of the cores. Hence, if only the antibodies against N-terminus or the mid-portion of the Aβ had been applied, the conclusion would have been that the iAβ is seen in all cases from 2 year old up to 100 year old irrespective of condition. This is in agreement with reports claiming that the iAβ represents a product of normal neuronal metabolism [23, 25, 34] . On the contrary, if only the antibodies directed to C-terminus of the Aβ had been used, the conclusion would have been that the iAβ is only detected in the brains of subjects with AD, and this would confirm the reports suggesting that the accumulation of iAβ is an event associated with the pathogenesis of AD [4, 7, 11, 13, 17, 45] . These results emphasize that the obtained staining results and their interpretation are strongly dependent on the choice of antibody and thus, it has to be concluded that indeed multiple antibodies, including antibodies directed to the N-and C-terminal neoepitopes, must be used when assessing the presence of iAβ [46] .
In the present study, in all cases (TMAa and TMAd) independent of disease state or age intracellular staining was seen with the antibodies 4G8, 6E10, and 82E1. The assessment of mirror images of consecutive sections revealed that not only the Aβ clones 4G8 and 6E10 but also the AβPP22C11 labeled the cytoplasm of the same cell. In 1996, LeBlanc and co-workers demonstrated that the clone 4G8 immunoprecipitated not only Aβ but also the full-length AβPP and AβPP C-terminal fragment [47] . This finding was further confirmed in 2002 by Takahashi and colleagues who reported that clone 4G8 reacted with AβPP C-terminal fragments in Western blotting [34] . The antibodies directed close to the N-terminus may theoretically also recognize Aβ that is still embedded in the membrane. The amino acid sequence that is recognized by clones 4G8 and 6E10 is also found in the full-length AβPP and its derivatives, hence these antibodies are unable to differentiate Aβ from AβPP [32, 33, 47, 48] . The clone 82E1 that detects fragments generated by β-secretase cleavage [48] labels both soluble and insoluble Aβ to a similar degree and recognizes the free N-terminus of the AβPP C99 fragment and this C99 fragment is then later cleaved by the γ-secretase to generate Aβ. Therefore, the detection of intracellular IR with clone 82E1 only indicates that the cleavage product of β-secretase is present in the intracellular compartment. The commonly used antibodies such as 4G8, 6E10, and 82E1 fail to distinguish Aβ from AβPP if examined by IHC. Thus, one must question the validity of reports claiming that it is Aβ rather than AβPP that is present in the intracellular compartment if antibodies such as 4G8, 6E10, and 82E1 have been utilized (Table 1) .
The accumulation of iAβ has also been reported while applying commercial antibodies directed to the C-terminus of Aβ (neoepitope) that have been reported to be specific to Aβ [3, 4, [7] [8] [9] 11, 13, [15] [16] [17] 19, 22, 23, 39] . In the present study, while applying commercial antibodies directed to the C-terminus of Aβ, an intense eAβ IR (positive control) was seen in the TMAa and TMAd core samples. In the TMAa, no iAβ was detected in any of the cores irrespective of whether or not additional eAβ was seen. Our negative result, i.e., lack of intracellular labeling while applying antibodies directed to Aβ 40 and Aβ 42 is confirmation of the reports of Kuo and co-workers and Mochizuki and coworkers [15, 49] . Contrary to the above, in all subjects with AD, intracellular IR was indeed detected with the antibodies directed to C-terminal neoepitopes Aβ 40 and Aβ 42 . The presence of iAβ in subjects with additional eAβ aggregates and widespread neuronal degeneration (Braak stages IV to VI) and the absence of iAβ in subjects without additional eAβ aggregates does suggest that it is the internalization of Aβ from the extracellular pool rather than the intracellular production of Aβ is accelerated. This finding is in line with several previous studies reporting the presence of iAβ in the AD brains [3, 4, [7] [8] [9] 11, 15, 17, 19, 22, 23, 39] . In 2008, Aoki and colleagues, while using laser capture micro dissection to isolate neurons of hippocampus, noted iAβ 42 in all investigated subjects [50] . They detected a significant increase in the level of iAβ 42 in AD subjects when compared with controls (mean age ranging from 71 to 90) and the highest levels were seen in subjects with familial disease [50] . Thus, the lack of IR in the brains obtained from subjects without neuronal degeneration may indicate that the level of the iAβ is very low, undetectable at the light microscopic level by IHC methods. In conclusion, our and previous results indicate that iAβ labeling with the specific antibodies can indeed be seen at the light microscopy level and this is associated with eAβ labeling but only in tissue samples obtained from diseased brains with widespread neuronal degeneration.
The antigen retrieval method, re-exposing and reshaping the critical epitopes, is significant as is shown in this study while applying clones 6E10 and 82E1 [5, 19, 21, [37] [38] [39] . Formic acid is a widely used antigen retrieval method to enhance the IR of eAβ, whereas the effect of formic acid pretreatment on the iAβ is less clear. In the present study, the intracellular IR with clones 6E10 and 82E1 was only seen when the sections were both heated and incubated in formic acid indicating that heat pretreatment was essential for the staining of iAβ with these antibodies. This result is in line with previous publications stating that formic acid pretreatment alone is not sufficient to visualize the intracellular IR [19, 39] . In the recently published study of Christensen and colleagues, it was demonstrated that heat alone increases the cross-reaction at least of clone 4G8 and AβPP [5] , i.e., this heat-induced cross-reaction may explain the more intense intracellular IR with clone 4G8. This result corroborates that it is AβPP rather than Aβ that is present in the intracellular compartment with antibody such as 4G8. The other antibody directed close to the N-terminus of the Aβ, clone 6F3D, repeatedly failed to label the intracellular compartment even though the extracellular labeling of aggregates was excellent. As far as we are aware, no intracellular labeling with clone 6F3D has been so far detected. Whether this is due to poor preservation of the epitope during pre-sectioning treatment, the spatial configuration of the protein, or the localization of the epitopes within the protein, is currently unknown [40, 51] .
In addition to the antibody and the antigen retrieval method, species differences may also influence on the staining results [35, 36] . All widely used transgenic mice models are based on AβPP mutations that are known to influence the production and aggregation of Aβ 42 peptide and thus Aβ peptides in transgenic mice models are in a higher aggregation state when compared to humans [5] . Moreover, it has been shown in vivo that transcription factors responsible for gene expression diverge between human and mouse [52] . Lately the epigenetic alterations have been linked to the development of neurological disorders such as AD and Parkinson disease [53] . It can be expected that like transcription factors also the epigenetic factors, DNA methylation and histone modifications, diverge between human and animals. These physiological differences affect all studies that use the mouse as a model for human biology [52] . Therefore, the results obtained from animal studies are not as such directly comparable with results obtained while studying brain tissue obtained from humans.
As shown in the present study, the obtained staining results are strongly dependent on the applied antibody, antigen retrieval method, and the tissue characteristics. Furthermore, it should be noted that the interpretation of the results while applying one and the same antibody has been contradictory, i.e., in one study the IR has been interpreted as representing Aβ and in another as AβPP [3, 32, 33] . Summarizing all the available reports (Table 1) and our own results, we conclude that at the light microscopic level it is not possible to differentiate Aβ from AβPP, when monoclonal antibodies such as 4G8, 6E10, and 82E1 have been used. In routine diagnostics while assessing the extracellular accumulation of Aβ, these antibodies are commendable, but they are not useful if one is trying to investigate the intracellular accumulation of Aβ. When the goal is to assess Aβ protein, and to determine whether protein is localized in the intracellular space, then antibody directed to neoepitopes that recognize the site of terminal sequence of Aβ and which are able to differentiate Aβ from AβPP should be used. In conclusion, if one wishes to unambiguously confirm the presence or absence of a protein in tissue, multiple antibodies directed to several different amino acid sequences should be used and the significant influence of antigen retrieval methods should also always be considered. Authors' disclosures available online (http://www.jalz.com/disclosures/view.php?id=303).
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